Obesity Treatment Market Research Report Information By Surgery Type (Biliopancreatic diversion with Duodenal Switch (BPD/DS), Adjusting Gastric Banding, Roux-en-Y Gastric Bypass, Sleeve gastrectomy, and Endoscopic Procedures), By Diagnosis (Appetite suppressants, Combination drugs, Malabsorption, and Satiety drugs), By End-User (Hospitals, and Clinics), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032

Global Obesity Treatment Market Overview

The Obesity Treatment Market Size was valued at USD 12.6 billion in 2023. The Obesity Treatment market industry is projected to grow from USD 14.71 Billion in 2024 to USD 32.3 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.32 % during the forecast period (2024 - 2032). Unhealthy eating habits and a sedentary lifestyle are the leading causes of obesity. The growing number of nuclear families and families with working parents is causing a shift in changing eating habits. These are the key market drivers enhancing market growth.

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Obesity Treatment Market Trends

• Increasing awareness regarding obesity treatment to boost the market growth

Obesity poses a considerable challenge to both developed and low- and middle-income economies. According to the World Health Organization fact paper, being overweight and obese are associated with various diseases and lead to higher mortality rates than undernutrition. Overweight and obese populations report a high prevalence of chronic diseases, including hypertension, diabetes, and orthopedic disease.

In addition, shifting preferences towards a sedentary lifestyle, lack of physical activity, and changes in eating habits lead to weight gain in adolescents. The rise in single-person households, nuclear families, and households with working parents is leading to the adoption of unhealthy lifestyles, driving the demand for convenient and inexpensive fast food. Busier schedules and increased stress lead people to consume ready-to-eat foods. Furthermore, young people's food consumption tendencies towards overeating and low nutrient intake can lead to adverse health effects. A growing number of obese teens and overweight people over 18 are rising due to physical inactivity, constant video game playing, and prolonged TV viewing.

For those in the industry, the weight loss and weight control diets market in the Asia Pacific holds excellent growth potential. This may be related to rising disposable income and adopting Western lifestyles, which are the key drivers for market expansion. Additionally, the segment may present opportunities for market players to launch premium, low-calorie items. Manufacturers focus on growing their companies in this segment to expand their consumer base and geographic reach. Moreover, Latin American countries such as Brazil are expected to present lucrative weight loss and weight management diet market prospects throughout the forecast period owing to the high prevalence of obesity in the Region. Therefore, the Obesity Treatment market CAGR has been increasing ly in recent years. These are essential factors driving the Obesity Treatment market revenue growth.

Obesity Treatment Market Segment Insights

Obesity Treatment Surgery Type Insights

Based on surgery type, the  Obesity Treatment market segmentation includes Biliopancreatic diversion with Duodenal Switch (BPD/DS), Adjusting Gastric Banding, Roux-en-Y Gastric Bypass, Sleeve gastrectomy, and Endoscopic Procedures. The Roux-en-Y segment held the majority share in 2022, contributing most of the  Obesity Treatment market revenue. The Roux-en-Y gastric bypass (RYGB) technique remains one of the best ways to lose weight, with an average weight loss of around 70% after one year. Several variables, including numerous government activities surrounding the issue of being overweight, technological developments in the medical field, and the commercially easy availability of weight management treatments, are driving the market.

Introducing innovative technologies and treatments with minimal side effects is a significant focus of many businesses. In addition, researchers have been trying to rewire white blood cells to behave more like brown fat cells. In this idea, fat cells are said to "exist." If they are successful, they can create a treatment to speed up the body's fat-burning process.

Obesity Treatment Diagnosis Insights

Diagnosis has bifurcated the  Obesity Treatment market data into Appetite suppressants, Combination drugs, Malabsorption, and Satiety drugs. Appetite suppressants have a considerable share of the market. Supplements called appetite suppressants work by suppressing hunger, which reduces food consumption and aids in weight loss. Only the drug orlistat should be considered. One of the medicines doctors recommend to help you lose weight is orlistat (Xenical). However, doctors recommend the drug only when dietary changes and exercise have failed to help patients lose weight, and their weight seriously threatens their health. People should combine drug therapy with a low-calorie diet. Orlistat is not a substitute for lifestyle changes. It has various side effects, including headaches and gastrointestinal problems such as greasy stools and irregular urination.

Figure 1 Obesity Treatment Market by End-User, 2023 & 2030 (USD billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Obesity Treatment End-User Insights

Based on End-User, the Obesity Management market segmentation has been segmented into hospitals and clinics. The academic & government research institute segment is expected to contribute a higher market share due to the wide acceptance of Sanger techniques and NGS in academic and institutional research projects. Moreover, rising funding and investment plans increase these entities' demand for Obesity Treatment Types, leading to a more significant revenue share.

Obesity Treatment Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Obesity Treatment market, which accounted for USD 4.94 billion in 2022, is expected to exhibit a significant CAGR growth during the study period. Urbanization is considered one of the leading causes of obesity. Thus, North America recently accounted for the largest market share of more than 53%. Furthermore, high R&D developments, minimally invasive procedures, and effective weight management solutions in the Region are the significant factors contributing to the growth of the obesity treatment market.

Further, the significant countries studied in the market report are The U.S., Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 OBESITY TREATMENT MARKET SHARE BY REGION 2023 (%)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe's Obesity Treatment market accounts for the second-largest market share. Europe contributes significantly to the revenue of the obesity management market. High intake of processed meat and the high prevalence of lifestyle diseases have exacerbated the obesity problem in the Region. The availability of obesity management health programs and government-led obesity management health centers heralds the growth of the obesity management market in this Region. Further, the German Obesity Treatment market held the largest market share, and the U.K. Obesity Treatment market was the fastest-growing market in the European Region.

The Asia-Pacific Obesity Treatment Market is expected to grow at the fastest CAGR from 2024 to 2030 due to growing awareness of health issues associated with obesity and social media exposure. Advanced medical facilities and infrastructure in the Region are also significant reasons for the growth of the obesity treatment market in these regions. Moreover, the China Obesity Treatment market held the largest market share, and the Indian Obesity Treatment market was the fastest-growing market in the Asia-Pacific region.

Obesity Treatment Key Market Players & Competitive Insights

Major market players are spending a lot on R&D to increase their Type lines, which will help the Obesity Treatment market grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new Type launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Obesity Treatment industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Manufacturing locally to reduce operating costs is one of the primary business strategies manufacturers adopt in the Obesity Treatment industry to benefit clients and expand the market sector. The Obesity Treatment industry has provided medicine with some of the most significant benefits in recent years. In the Obesity Treatment markets, major players such as VIVUS, Inc. (U.S.), Arena Pharmaceuticals, Inc. (U.S.), F. Hoffmann-La Roche, Ltd. (Switzerland), Novo Nordisk A/S (Denmark), Orexigen Therapeutics, Inc. (U.S.), and others are working on expanding the market demand by investing in research and development activities.

Vivus (OTC VVUSQ) is a small pharmaceutical company headquartered in Campbell, California, focused on obesity, sleep, and sexual health. Vivus is developing an erectile dysfunction drug, Avanafil, which has completed phase 3 clinical trials. The drug has been approved by the FDA and will be marketed under Stendra. Stendra is the first and only oral ED treatment approved to be taken approximately 15 minutes before sexual activity.

Also, Arena Pharmaceuticals, Inc. is an American biopharmaceutical company founded in 1997 and headquartered in San Diego, California. [3] The company is developing small-molecule drugs with potential clinical applications in multiple therapeutic areas. The company's most advanced investigational clinical programs are ralinepag (formerly APD811) for the detection of pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) for the evaluation of inflammatory indications, and APD371 for the treatment of pain associated with Crohn's disease.

Key Companies in the Obesity Treatment market include

• VIVUS, Inc. (U.S.)


• Arena Pharmaceuticals, Inc. (U.S.)


• Hoffmann-La Roche, Ltd. (Switzerland)


• Novo Nordisk A/S (Denmark)


• Orexigen Therapeutics, Inc. (U.S.)


• Allergan (Republic of Ireland)


• Cousin Biotech (France)


• EnteroMedics, Inc. (U.S.)


• Johnson & Johnson Services, Inc. (U.S.)


• Medtronic (U.S.)


• USGI Medical, Inc. (U.S.)


• Mediflex Surgical Products (U.S.)


• Covidien plc (Republic of Ireland)


• Olympus Corporation (Japan)


• Takeda Pharmaceuticals Company Limited


• Eisai Co. Ltd.


• Novo Nordisk A/S


• Zafgen


• Rhythm Pharmaceuticals


• Zydus Cadila


• Norgine B.V.


• Vivus Therapeutics


• Arena Pharmaceuticals Inc.


• Orexigen Therapeutics Inc, among others

Obesity Treatment Industry Developments

February 2022 Pfizer. Research on an oral diabetes drug called glucagon-like peptide-1 receptor suggests that the drug can help manage type 2 diabetes and aid in weight loss since obesity is often associated with type 2 diabetes.

November 2021 Novo Nordisk announces that the European regulator, the Committee for Medicinal Products for Human Use (CHMP), has adopted a positive opinion and recommends marketing authorization of Wegovy for chronic weight management in obese adults.

Obesity Treatment Market Segmentation

Obesity Treatment Surgery Type Outlook

• Biliopancreatic diversion with Duodenal Switch (BPD/DS)


• Adjusting Gastric Banding


• Roux-en-Y Gastric Bypass


• Sleeve gastrectomy


• Endoscopic Procedures

Obesity Treatment Diagnosis Outlook

• Appetite suppressants


• Combination drugs


• Malabsorption


• Satiety drugs

Obesity Treatment End-User Outlook

• Hospitals


• Clinics

Obesity Treatment Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America